Preventive Pet Health: the Math Your Customer is Already Running

The pet owner who just paid $4,700 to manage a cardiac diagnosis in her seven-year-old Labrador is not a hard sell for a health monitoring device. She's the customer who already knows exactly what she would have paid for one two years ago.

That is the situation the preventive pet health category sits in right now. The consumer-side argument has already been made. Not by marketing. By vet bills.

The Mumbers Behind the Story

Pet owners are not instinctively frugal, but they are financially rational in ways brands often underestimate. When they say they want to catch things early, they are not only expressing love for their animal. They are expressing a preference for a $300 problem over a $3,000 one.

The data backs that preference in ways that are easy to quote and hard to argue with.

According to data published by dvm360, the average annual veterinary cost of managing canine heart disease runs to $1,912, with high-end cases reaching $4,693. Those figures represent ongoing management of a diagnosed condition. They do not include the initial diagnostic workup, which at the cardiac specialist level typically involves chest X-rays ($125-$200), an echocardiogram ($300-$1,000), and an ECG before any treatment plan is set.

Heartworm is the clearest comparison case in the category. According to Vetster, one round of heartworm treatment costs between $1,200 and $1,800 on average, and most dogs need at least two rounds. Prevention costs $70 to $200 per year for a 40-pound dog. The ratio is roughly 10 to 1 in favor of prevention. PetsNerd, citing AVMA data, puts the return on heartworm prevention at $80 to $500 saved per dollar spent.

For cancer, which affects approximately one in four dogs at some point in their lifetime and close to half of all dogs over ten, the early-detection argument is more consequential still. A 2021 review published in Frontiers in Veterinary Science found that, drawing on health economics studies across oncology, treatment costs for patients diagnosed early are two to four times lower than for those diagnosed at a late stage. Early-stage tumors are often resectable and curative. Late-stage management extends life rather than preserving it, and costs more for the privilege.

These numbers are not obscure. Pet owners find them. They find them at 11pm before a vet appointment, or in the comments section of a breed group, or from a friend who has been through it. By the time they are evaluating a health monitoring device, the cost comparison has usually already landed.

What the insurance market noticed

The insurance industry is not sentimental. It prices things based on what it expects to pay out, and what it expects to pay out is shaped by who is managing their pet's health proactively and who is not.

The US pet health insurance sector exceeded $5.2 billion in written premiums in 2024, according to the North American Pet Health Insurance Association (NAPHIA), up from $4.2 billion in 2023. The number of insured cats and dogs in the US grew 126 percent between 2019 and 2023. That growth is coming partly from millennials and Gen Z owners who treat their animals as dependents, and partly from a category that has learned how to price early-detection behavior.

Insurers are beginning to close the loop between wearable device usage and policy pricing. Covéa, one of the major European insurance groups, has partnered with Tractive to integrate wearable data into its underwriting process. Analysis from Spot Pet Insurance, citing IoT-driven data integration trends, notes that wearable data allows insurers to offer more precise pricing as real-time health metrics reduce the uncertainty that makes premiums expensive. A dog whose resting heart rate, activity patterns, and sleep quality are tracked continuously is a measurably different risk proposition than one whose health is checked once a year at an annual exam.

The direction is clear even where formal discount structures are not yet standardized across the market. Insurance companies follow claims data. Claims data follows outcomes. Outcomes follow the gap between how early a condition was caught and how advanced it was when it presented.

What "preventive" actually requires

The term preventive pet health is doing a lot of work in the market right now, and not all of it is honest. An activity tracker that logs steps is not the same category of product as a device that monitors heart rate, respiratory rate, and HRV continuously and flags deviations from the individual animal's baseline.

The difference matters for sourcing decisions because pet owners who have been through a serious health event are not fooled by the distinction. They know the vet visit that caught the problem was not a step count.

Genuine preventive monitoring requires continuous physiological data, not behavioral proxies. It requires a sensor architecture capable of detecting subtle changes in cardiac function before those changes produce visible symptoms. A dog with early-stage myxomatous mitral valve disease may show no symptoms for years. What changes first are the mechanical signals of cardiac effort. A BCG (ballistocardiography) sensor can detect those signals. An accelerometer cannot.

This is not an academic distinction. For a brand considering what to source, it is the line between a product that participates in the preventive pet health category in name and one that actually earns its position there.

The PHH-23

PuresPet's PHH-23 is a health monitoring device built around a BCG sensor architecture. It monitors heart rate, respiratory rate, body movement, and BCG waveform continuously, around the clock, and generates HRV reports, sleep analysis, and health summaries. Abnormal readings are flagged automatically through the companion app, which is compatible with Android and iOS.

Layered on top of the health monitoring is 4G Cat.1 cellular connectivity with full GPS positioning via GPS, BDS, AGPS, LBS, and Wi-Fi triangulation to a stated accuracy of three to five meters. The same device that sends a cardiac anomaly alert also sends an escape alert if the dog leaves the yard. At 125 x 34 x 14mm and 55 grams, it is best suited to medium and large breeds.

The PHH-23 is CE and FCC certified. PuresPet offers OEM and ODM services, which means the hardware can carry a brand's own identity through laser or screen-printed logo options and customized packaging. Minimum order quantity is 100 units per color per size. Sampling lead time is 7 to 10 days for customized versions.

For a brand that has been selling GPS collars and is now fielding customer questions about health data, it answers both questions in one device. For a brand entering the physiological monitoring category for the first time, it is a product that has already resolved the engineering problems that activity trackers have not.

The buyer who has already decided

The pet wearable market was valued at $3.4 billion in 2025 and is projected to reach $11.4 billion by 2033, according to Grand View Research, growing at a CAGR of 16.8 percent. That growth is not coming from people who are undecided about whether monitoring matters. It is coming from a buyer who has often already experienced what late detection costs.

That buyer is not persuaded into preventive pet health by a brand's content strategy. They arrive already persuaded. What they are evaluating is whether a brand has thought through the category seriously enough to offer a product worth their trust.

A device that produces a BCG waveform, tracks HRV against an individual baseline, and connects to a vet conversation with specific data is a product that earns that trust. A relabeled step counter is not.

The brand that is not in this category is not neutral. It is simply absent from a purchase decision that is already being made.

Frequently Asked Questions

What is preventive pet health, and why does it matter for dog owners?

Preventive pet health refers to the practice of monitoring and managing a dog's health before clinical symptoms appear, rather than waiting for a problem to become visible. This can include regular vet screenings, vaccinations, preventive medications for conditions like heartworm, and continuous health monitoring via wearable devices. The case for it is largely economic: treatment for conditions caught at an early stage consistently costs less than managing the same conditions at a late or emergency stage, in addition to the quality-of-life difference for the animal.

How much cheaper is early detection than late-stage treatment in dogs?

The gap varies by condition. For heartworm, prevention costs $70 to $200 per year, while treatment runs $1,200 to $1,800 per round and most dogs require at least two rounds. For cancer, a review published in Frontiers in Veterinary Science found that early-stage treatment costs two to four times less than late-stage treatment across comparable oncology cases. For heart disease, which costs an average of $1,912 annually in ongoing management costs according to dvm360, earlier detection changes the trajectory of care and can significantly reduce the cumulative financial exposure.

Do pet insurance companies factor in health monitoring devices when pricing policies?

Insurers are actively moving in this direction. Covéa has formalized a partnership with wearable provider Tractive to incorporate device data into underwriting. According to Spot Pet Insurance, IoT-enabled wearables allow insurers to offer more granular pricing as continuous health data reduces the uncertainty that drives up premiums. The formal discount structures are not yet universal, but the direction of the market is clear: a dog with continuous physiological monitoring represents a more knowable risk than one without.

What is a BCG sensor, and why does it matter for pet health devices? Ballistocardiography (BCG) is a sensor technology that detects the small mechanical movements produced by the body with each heartbeat. In the context of a pet health collar, it allows continuous monitoring of heart rate, respiratory rate, and the shape of the cardiac waveform itself, not just step count or gross body movement. This matters because many early-stage cardiac conditions, including the most common heart disease in dogs (myxomatous mitral valve disease), produce changes in the mechanical signals of the heart before they produce visible symptoms. A BCG sensor can track those changes. An accelerometer cannot.

What features should a pet health monitoring device include for it to qualify as genuine preventive care?

At a minimum: continuous monitoring of heart rate and respiratory rate, not just activity; an HRV (heart rate variability) tracking component; automated anomaly detection relative to the individual animal's baseline (not population averages); and data output that can be shared with a veterinarian in a readable format. A device that produces a BCG waveform and generates health reports a vet can act on is a substantively different product from one that tracks steps and sleep cycles via an accelerometer.

How large is the preventive pet health device market?

The global pet health monitoring devices market was valued at $3.6 billion in 2024 and is projected to reach $15.5 billion by 2035, according to MetaTech Insights, growing at approximately 14.2 percent annually. The broader pet wearable market, which includes GPS trackers and activity monitors alongside health monitoring devices, was valued at $3.4 billion in 2025 and is projected to reach $11.4 billion by 2033 (Grand View Research, CAGR of 16.8 percent). North America held 37 percent of global market share in 2025.

Is preventive pet health only relevant for older dogs?

No. While older dogs carry a statistically higher risk for conditions like cancer and heart disease, the value of a continuous baseline is established before a dog is sick. A device that has been monitoring a dog's resting heart rate and HRV for 18 months gives a veterinarian a meaningful reference point when something changes. A device deployed after a diagnosis has no baseline to compare against. The prevention case for starting early is identical to the argument for any health monitoring in humans: you need the data before you need it.